# A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema

> **NCT02281292** · PHASE1 · WITHDRAWN · sponsor: **Alcon Research**

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **BIOLOGICAL:** LKA651 ophthalmic solution
- **BIOLOGICAL:** Ranibizumab ophthalmic solution
- **BIOLOGICAL:** Sham injection

## Key facts

- **NCT ID:** NCT02281292
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Management Decision
- **Last updated:** 2015-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281292, "A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02281292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*